Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Udvardy Miklos, Vladimir Strugov, MD, Catharina Lewerin, MD PhD, Sebastian Grosicki, MD PhD, Grzegorz Mazur, MD PhD, Michael Steurer, MD, Marco Montillo, MD, Irina Kryachok, Prof., PhD, Jan Moritz Middeke, MD, Grygoriy Rekhtman, MD, Tommaso Stefanelli, Ghislaine Vincent, Sameera G, PhD, Anders Österborg, MD PhD Prof.

Blood (2018) 132 (Supplement 1): 5569.

https://doi.org/10.1182/blood-2018-99-113295

Published: 2018

Journal Articles

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Blood (2016) 127 (23): 2847–2855.

https://doi.org/10.1182/blood-2015-11-680074

Published: 2016

Includes: Supplemental data

Journal Articles

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegel, Wolfgang Schimetta, Bettina Gisslinger, Reinhard Ruckser, Martin Schalling, MSc, Guenther A. Gastl, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2814.

https://doi.org/10.1182/blood.V126.23.2814.2814

Published: 2015

Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 1996.

https://doi.org/10.1182/blood.V124.21.1996.1996

Published: 2014

Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Blood (2014) 124 (21): 20.

https://doi.org/10.1182/blood.V124.21.20.20

Published: 2014

Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta

Blood (2014) 124 (21): 4684.

https://doi.org/10.1182/blood.V124.21.4684.4684

Published: 2014

Journal Articles

Prevalence of the JAK2 V617F Mutation in Patients with Peripheral Arterial Disease

Elena Kinz, Klaus Gasser, MD, Axel Muendlein, PhD, Andreas Leiherer, PhD, Michael Steurer, Peter Fraunberger, MD, Alois Lang, MD, Heinz Drexel, MD

Blood (2014) 124 (21): 3165.

https://doi.org/10.1182/blood.V124.21.3165.3165

Published: 2014

Journal Articles

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Francesco Rodeghiero, Andrew Provan, Michael Steurer, MD, Bertrand Godeau, MD, Nancy Carpenter, MSc, Georg Kreuzbauer, MD

Blood (2014) 124 (21): 4199.

https://doi.org/10.1182/blood.V124.21.4199.4199

Published: 2014

Journal Articles

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegl, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2014) 124 (21): 1863.

https://doi.org/10.1182/blood.V124.21.1863.1863

Published: 2014

Journal Articles

Determination of Driver Mutations in JAK2, MPL, and Calreticulin in Coronary Patients with Suspected Essential Thrombocythemia

Klaus Gasser, MD, Axel Muendlein, PhD, Elena Kinz, Andreas Leiherer, PhD, Michael Steurer, Peter Fraunberger, MD, Heinz Drexel, MD, Alois Lang, MD

Blood (2014) 124 (21): 5552.

https://doi.org/10.1182/blood.V124.21.5552.5552

Published: 2014

Journal Articles

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Dietrich Sascha, MD, Andreas Pircher, MD, Mindaugas Andrulis, MD, Elena Ellert, MD, Frédéric Peyrade, Clemens-Martin Wendtner, MD, George A Follows, Martin JS Dyer, Thomas Elter, MD, Robert Zeiser, Anita Gaehler, MD, Michael Herrmann, Michael Herold, MDPhD, Claire Dearden, MD, Hanno Glimm, MD, Michael Hallek, MD, Anthony D Ho, MD, Michael Steurer, Thorsten Zenz, MD

Blood (2014) 124 (21): 3634.

https://doi.org/10.1182/blood.V124.21.3634.3634

Published: 2014

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1635.

https://doi.org/10.1182/blood.V122.21.1635.1635

Published: 2013

Journal Articles

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Alexander Egle, Michael Steurer, MD, Franz Josef Gassner, PhD, Roland Geisberger, Thomas Melchardt, MD, Lisa Pleyer, MD, DI, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2013) 122 (21): 4164.

https://doi.org/10.1182/blood.V122.21.4164.4164

Published: 2013

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

Journal Articles

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Blood (2012) 120 (21): 2839.

https://doi.org/10.1182/blood.V120.21.2839.2839

Published: 2012

Journal Articles

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Dominik Selleslag, Ann Janssens, Hans Wadenvik, Michael Steurer, MD, Philippe Quittet, MD, Georgia Kaiafa, Tomas Kozak, MD, Helen Papadaki, Jean-François Viallard, MD, PhD, Kerry Dillingham, Georg Kreuzbauer, MD

Blood (2012) 120 (21): 3316.

https://doi.org/10.1182/blood.V120.21.3316.3316

Published: 2012

Journal Articles

Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,

Blood (2011) 118 (21): 3559.

https://doi.org/10.1182/blood.V118.21.3559.3559

Published: 2011

Journal Articles

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Ann Janssens, MD, Michael D. Tarantino, MD, Robert Bird, MD, Maria Gabriella Mazzucconi, MD, Ralph Vincent V. Boccia, MD, Maria Fernanda Lopez-Fernandez, MD, Tomas Kozak, MD, Michael Steurer, MD, Peter A.W. Te Boekhorst, MD, PhD, Kerry Dillingham, MSc, Richard Lizambri, MD

Blood (2011) 118 (21): 3279.

https://doi.org/10.1182/blood.V118.21.3279.3279

Published: 2011

Journal Articles

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Alexander Egle, MD, Michael Steurer, MD, Franz Gassner, Roland Geisberger, PhD, Thomas Melchardt, MD, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2011) 118 (21): 292.

https://doi.org/10.1182/blood.V118.21.292.292

Published: 2011

NARROW

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Prevalence of the JAK2 V617F Mutation in Patients with Peripheral Arterial Disease

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Determination of Driver Mutations in JAK2, MPL, and Calreticulin in Coronary Patients with Suspected Essential Thrombocythemia

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only